Vertex Pharmaceutic Stock Target Price and Analyst Consensus

VRTX
 Stock
  

USD 291.16  2.18  0.75%   

The current analyst and expert consensus on Vertex Pharmaceutic is Buy with 5 hold recommendations. The current projected Vertex Pharmaceutic target price consensus is 259.89 with 19 analyst opinions. One of the most common ways Vertex Pharmaceutic analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Vertex Pharmaceutic vendors, executives, and/or customers. Vertex Pharmaceutic recommendation module provides expert sentiment on the projected Vertex Pharmaceutic target price to derive its highest and lowest estimates based on target price standard deviation of 38.176. Also, please take a look at Macroaxis Advice on Vertex Pharmaceutic to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
Refresh
Gross Profit is likely to rise to about 1.4 B in 2022. Profit Margin is likely to rise to 33.36 in 2022. Vertex Pharmaceutic Deferred Revenue is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Deferred Revenue of 14.53 Million in 2021. Shareholders Equity is likely to rise to about 10.9 B in 2022, whereas Debt Non Current is likely to drop slightly above 415.6 M in 2022.

Vertex Pharmaceutic Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vertex target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions19
Lowered Outlook0
Raized Outlook0
Buy
Most Vertex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vertex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vertex Pharmaceutic, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Vertex Pharmaceutic Target Price Projection

Vertex Pharmaceutic's current and average target prices are 291.16 and 259.89, respectively. The current price of Vertex Pharmaceutic is the price at which Vertex Pharmaceutic is currently trading. On the other hand, Vertex Pharmaceutic's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Vertex Pharmaceutic Market Quote on 7th of July 2022

Low Price288.27Odds
High Price293.62Odds

291.16

Target Price

Analyst Consensus On Vertex Pharmaceutic Target Price

Low Estimate201.0Odds
High Estimate341.0Odds
Number of Analysts19
Standard Deviation38.176

259.894

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Vertex Pharmaceutic and the information provided on this page.

Vertex Pharmaceutic Analyst Ratings

Vertex Pharmaceutic's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Vertex Pharmaceutic stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Vertex Pharmaceutic's financials, market performance, and future outlook by experienced professionals. Vertex Pharmaceutic's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Vertex Pharmaceutic Target Price Projections

Vertex Pharmaceutic's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Vertex Pharmaceutic and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Vertex depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Vertex Pharmaceutic including analysis of its current option contracts.
Vertex Pharmaceutic's latest option contracts expiring on 2022-07-08 are carrying combined implied volatility of 67.2 with a put-to-call open interest ratio of 0.22 over 120 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2022-07-08. The current put volume is at 169, with calls trading at the volume of 150. This yields a 1.13 put-to-call volume ratio. The Vertex Pharmaceutic option chain provides detailed quote and price information for the current Vertex Pharmaceutic option contracts. It shows all of Vertex Pharmaceutic's listed puts, calls, expiration dates, strike prices, and other pricing information.

Open Interest Against 2022-07-08 Option Contracts

Vertex Pharmaceutic option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Vertex Pharmaceutic's lending market. For example, when Vertex Pharmaceutic's puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Vertex Pharmaceutic, he or she must hedge the risk by shorting Vertex Pharmaceutic stock over its option's life.
The chart above shows Vertex Pharmaceutic's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Vertex Pharmaceutic's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Vertex Pharmaceutic's option, there is no secondary market available for investors to trade.

Vertex Pharmaceutic Maximum Pain Price across 2022-07-08 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Vertex Pharmaceutic close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Vertex Pharmaceutic's stock options are financial instruments that give investors the right to buy or sell shares of Vertex Pharmaceutic common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Vertex stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Vertex Pharmaceutic's stock price goes up or down, the stock options follow.
Also, please take a look at Macroaxis Advice on Vertex Pharmaceutic to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Vertex Pharmaceutic In The Money Call Balance

When Vertex Pharmaceutic's strike price is surpassing the current stock price, the option contract against Vertex Pharmaceutic stock is said to be in the money. When it comes to buying Vertex Pharmaceutic's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' options written on Vertex Pharmaceutic are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Vertex Current Options Market Mood

Vertex Pharmaceutic's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Vertex Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Vertex Pharmaceutic's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Vertex Pharmaceutic's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Vertex Pharmaceutic's option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Additional Vertex Pharmaceutic Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Vertex Pharmaceutic is a key component of Vertex Pharmaceutic valuation and have some predictive power on the future returns of a Vertex Pharmaceutic.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Vertex Pharmaceutic's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Vertex Pharmaceutic in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
288.37290.85293.33
Details
Intrinsic
Valuation
LowReal ValueHigh
241.02243.50320.28
Details
Naive
Forecast
LowNext ValueHigh
307.55310.03312.51
Details
Earnings
Estimates (9)
LowProjected EPSHigh
11.4011.6011.81
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Vertex Pharmaceutic. Your research has to be compared to or analyzed against Vertex Pharmaceutic's peers to derive any actionable benefits. When done correctly, Vertex Pharmaceutic's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Vertex Pharmaceutic.

Additional Vertex Pharmaceutic Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Vertex Pharmaceutic is a key component of Vertex Pharmaceutic valuation and have some predictive power on the future returns of a Vertex Pharmaceutic.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Vertex Pharmaceutic's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Vertex Pharmaceutic in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
288.37290.85293.33
Details
Intrinsic
Valuation
LowReal ValueHigh
241.02243.50320.28
Details
Naive
Forecast
LowNext ValueHigh
307.55310.03312.51
Details
Earnings
Estimates (9)
LowProjected EPSHigh
11.4011.6011.81
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Vertex Pharmaceutic. Your research has to be compared to or analyzed against Vertex Pharmaceutic's peers to derive any actionable benefits. When done correctly, Vertex Pharmaceutic's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Vertex Pharmaceutic.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Software
Invested over 20 shares
Millennials Best
Invested over 70 shares
Macroaxis Index
Invested few shares
Cars
Invested over 200 shares
Also, please take a look at Macroaxis Advice on Vertex Pharmaceutic to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
The data published in Vertex Pharmaceutic's official financial statements usually reflect Vertex Pharmaceutic's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vertex Pharmaceutic. For example, before you start analyzing numbers published by Vertex accountants, it's critical to develop an understanding of what Vertex Pharmaceutic's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Vertex Pharmaceutic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vertex Pharmaceutic's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vertex Pharmaceutic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceutic. Please utilize our Beneish M Score to check the likelihood of Vertex Pharmaceutic's management to manipulate its earnings.